Repligen to Report Second Quarter 2019 Financial Results
July 23 2019 - 4:01PM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its second quarter 2019 financial results on Thursday,
August 1, 2019. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the three- and
six-month reporting periods ended June 30, 2019.
The conference call will be accessible by
dialing toll-free (844) 701-1063 for domestic callers and (412)
317-5487 for international callers. No passcode is required for the
live call. In addition, a webcast will be accessible via
the Investor Relations section of the Company’s website. Both
the conference call and webcast will be archived for a period of
time following the live event. The replay dial-in numbers are (877)
344-7529 for callers in the U.S., (855) 669-9658 for callers in
Canada and (412) 317-0088 for international callers. Replay
listeners must provide the passcode 10133911.
About Repligen
CorporationRepligen Corporation is a global bioprocessing
company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug
manufacturers worldwide. Repligen’s corporate headquarters are in
Waltham, MA (USA), with additional administrative and manufacturing
operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez,
CA; Lund, Sweden; Breda, The Netherlands and Ravensburg,
Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Repligen Contact: Sondra
S. NewmanGlobal Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024